Payables and other current liabilities |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2025 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trade and other current payables [abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Payables and other current liabilities | Payables and other current liabilitiesNote 17.1. Trade payables and other current liabilities Trade payables and other current liabilities break down as follows:
The increase in accrued invoices as of June 30, 2025 compared to December 31, 2024 is mainly explained by upcoming milestones and increased activity on ABTECT reflecting the progress on phase 3 clinical trials. Note 17.2. Tax and employee-related payablesTax and employee-related payables are presented below:
|